This week, the FDA issues an EUA for tocilizumab in COVID-19; an electronic tool detects ovarian and pancreatic cancers; the delta variant accounts for 20% of new COVID-19 cases; researchers uncover variables linked with COVID-19 fatalities; and the ACIP recommends the dengue vaccine for children in endemic areas.

Read the full coverage here:

FDA issues EUA for tocilizumab to treat patients hospitalized with COVID-19

‘Electronic nose’ accurately detects ovarian, pancreatic cancers

Fauci: 20% of new COVID-19 cases are from delta variant

Researchers identify variables associated with COVID-19 fatalities during first wave

ACIP unanimously recommends dengue vaccine for children aged 9 to 16 years

References:

CDC. Advisory Committee on Immunization Practices. https://www.cdc.gov/vaccines/acip/index.html. Accessed June 24, 2021.

FDA press release.

Genentech press release.

Johnson ATC, et al. Abstract 9004. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Millar JA, et al. Risk factors for increased COVID-19 case-fatality in the United States: A county-level analysis during the first wave. Presented at World Microbe Forum; June 20-24, 2021 (virtual meeting).